Literature DB >> 7492080

Mechanism of inhibition of duck hepatitis B virus polymerase by (-)-beta-L-2',3'-dideoxy-3'-thiacytidine.

A Severini1, X Y Liu, J S Wilson, D L Tyrrell.   

Abstract

We have used the endogenous reverse transcriptase reaction of viral core particles from duck liver to elucidate the mechanism of inhibition of duck hepatitis B virus (DHBV) replication by the nucleoside analog (-)-beta-L-2',3'-dideoxy-3'-thiacytidine (3TC). As is the case in human immunodeficiency virus replication, 3TC-5'-triphosphate (3TC-TP) acts as a chain terminator for the DNA polymerase activities. The results of several different experiments support this conclusion, which explains the potent activity of 3TC against the hepadnaviruses. In isolated DHBV core particles, 3TC-TP inhibited the reverse transcriptase in a manner that resembled competitive inhibition with respect to dCTP. However, the kinetics of inhibition was not linear on a double-reciprocal plot for the highest concentrations of 3TC-TP and the lowest concentration of dCTP. This anomaly would be expected if binding to the nucleotide site was followed by DNA chain termination. Calculations that used only the linear part of the curve yielded a Ki of 0.78 +/- 0.10 microM 3TC-TP. The inhibition of core particles incubated in vitro with 3TC-TP was not reversed by removal of the free inhibitor. 3TC-TP inactivated the reverse transcriptase activity in a concentration-dependent manner. The Km of the chain termination reaction was calculated at 0.71 +/- 0.05 microM. Similar competitive kinetics and irreversible inhibition were also obtained on the endogenous DNA polymerase from viral particles from serum, suggesting that 3TC-TP also acts as a chain terminator of the DNA-directed DNA polymerase of DHBV replication.(ABSTRACT TRUNCATED AT 250 WORDS)

Entities:  

Mesh:

Substances:

Year:  1995        PMID: 7492080      PMCID: PMC162757          DOI: 10.1128/AAC.39.7.1430

Source DB:  PubMed          Journal:  Antimicrob Agents Chemother        ISSN: 0066-4804            Impact factor:   5.191


  31 in total

1.  A system for studying the selective encapsidation of hepadnavirus RNA.

Authors:  J Lavine; R Hirsch; D Ganem
Journal:  J Virol       Date:  1989-10       Impact factor: 5.103

2.  Initiation and termination of duck hepatitis B virus DNA synthesis during virus maturation.

Authors:  J M Lien; D J Petcu; C E Aldrich; W S Mason
Journal:  J Virol       Date:  1987-12       Impact factor: 5.103

3.  Adenylyl imidodiphosphate, an adenosine triphosphate analog containing a P--N--P linkage.

Authors:  R G Yount; D Babcock; W Ballantyne; D Ojala
Journal:  Biochemistry       Date:  1971-06-22       Impact factor: 3.162

4.  Replication of the genome of a hepatitis B--like virus by reverse transcription of an RNA intermediate.

Authors:  J Summers; W S Mason
Journal:  Cell       Date:  1982-06       Impact factor: 41.582

5.  Inhibition of human and woodchuck hepatitis virus DNA polymerase by the triphosphates of acyclovir, 1-(2'-deoxy-2'-fluoro-beta-D-arabinofuranosyl)-5-iodocytosine and E-5-(2-bromovinyl)-2'-deoxyuridine.

Authors:  O Hantz; H S Allaudeen; T Ooka; E De Clercq; C Trepo
Journal:  Antiviral Res       Date:  1984-08       Impact factor: 5.970

6.  Protein covalently bound to minus-strand DNA intermediates of duck hepatitis B virus.

Authors:  K L Molnar-Kimber; J Summers; J M Taylor; W S Mason
Journal:  J Virol       Date:  1983-01       Impact factor: 5.103

7.  In vitro experimental infection of primary duck hepatocyte cultures with duck hepatitis B virus.

Authors:  J S Tuttleman; J C Pugh; J W Summers
Journal:  J Virol       Date:  1986-04       Impact factor: 5.103

8.  Factors determining the activity of 2',3'-dideoxynucleosides in suppressing human immunodeficiency virus in vitro.

Authors:  Z Hao; D A Cooney; N R Hartman; C F Perno; A Fridland; A L DeVico; M G Sarngadharan; S Broder; D G Johns
Journal:  Mol Pharmacol       Date:  1988-10       Impact factor: 4.436

9.  Inhibition of human immunodeficiency virus type 1 reverse transcriptase by the 5'-triphosphate beta enantiomers of cytidine analogs.

Authors:  A Faraj; L A Agrofoglio; J K Wakefield; S McPherson; C D Morrow; G Gosselin; C Mathe; J L Imbach; R F Schinazi; J P Sommadossi
Journal:  Antimicrob Agents Chemother       Date:  1994-10       Impact factor: 5.191

10.  The amino-terminal domain of the hepadnaviral P-gene encodes the terminal protein (genome-linked protein) believed to prime reverse transcription.

Authors:  R Bartenschlager; H Schaller
Journal:  EMBO J       Date:  1988-12-20       Impact factor: 11.598

View more
  34 in total

1.  The intracellular activation of lamivudine (3TC) and determination of 2'-deoxycytidine-5'-triphosphate (dCTP) pools in the presence and absence of various drugs in HepG2 cells.

Authors:  S Kewn; P G Hoggard; S D Sales; M A Johnson; D J Back
Journal:  Br J Clin Pharmacol       Date:  2000-12       Impact factor: 4.335

Review 2.  Treatment of chronic hepatitis B: new antiviral therapies.

Authors:  F Yao; R G Gish
Journal:  Curr Gastroenterol Rep       Date:  1999 Feb-Mar

3.  Cross-resistance testing of antihepadnaviral compounds using novel recombinant baculoviruses which encode drug-resistant strains of hepatitis B virus.

Authors:  W E Delaney; R Edwards; D Colledge; T Shaw; J Torresi; T G Miller; H C Isom; C T Bock; M P Manns; C Trautwein; S Locarnini
Journal:  Antimicrob Agents Chemother       Date:  2001-06       Impact factor: 5.191

4.  Line probe assay for monitoring drug resistance in hepatitis B virus-infected patients during antiviral therapy.

Authors:  L Stuyver; C Van Geyt; S De Gendt; G Van Reybroeck; F Zoulim; G Leroux-Roels; R Rossau
Journal:  J Clin Microbiol       Date:  2000-02       Impact factor: 5.948

5.  Dynamics of hepatitis B virus resistance to lamivudine.

Authors:  Coralie Pallier; Laurent Castéra; Alexandre Soulier; Christophe Hézode; Patrice Nordmann; Daniel Dhumeaux; Jean-Michel Pawlotsky
Journal:  J Virol       Date:  2006-01       Impact factor: 5.103

6.  Early detection and quantification of lamivudine-resistant hepatitis B virus mutants by fluorescent biprobe hybridization assay in lamivudine-treated patients.

Authors:  Fumi Umeoka; Yoshiaki Iwasaki; Masayuki Matsumura; Akinobu Takaki; Haruhiko Kobashi; Masashi Tatsukawa; Hidenori Shiraha; Shin-ichi Fujioka; Kohsaku Sakaguchi; Yasushi Shiratori
Journal:  J Gastroenterol       Date:  2006-07       Impact factor: 7.527

7.  Mutations outside the YMDD motif in the P protein can also cause DHBV resistant to Lamivudine.

Authors:  Jin-Yang He; Yu-Tong Zhu; Rui-Yi Yang; Li-Ling Feng; Xing-Bo Guo; Feng-Xue Zhang; Hong-Shan Chen
Journal:  World J Gastroenterol       Date:  2005-07-21       Impact factor: 5.742

8.  New enzyme immunoassay for detection of hepatitis B virus core antigen (HBcAg) and relation between levels of HBcAg and HBV DNA.

Authors:  Tatsuji Kimura; Akinori Rokuhara; Akihiro Matsumoto; Shintaro Yagi; Eiji Tanaka; Kendo Kiyosawa; Noboru Maki
Journal:  J Clin Microbiol       Date:  2003-05       Impact factor: 5.948

9.  Generation of duck hepatitis B virus polymerase mutants through site-directed mutagenesis which demonstrate resistance to lamivudine [(--)-beta-L-2', 3'-dideoxy-3'-thiacytidine] in vitro.

Authors:  K P Fischer; D L Tyrrell
Journal:  Antimicrob Agents Chemother       Date:  1996-08       Impact factor: 5.191

Review 10.  Targeting hepatitis B therapy to the liver. Clinical pharmacokinetic considerations.

Authors:  P C Rensen; R L de Vrueh; T J van Berkel
Journal:  Clin Pharmacokinet       Date:  1996-08       Impact factor: 6.447

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.